Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06027788 · ClinicalTrials.gov registry record · NA

CTSN Embolic Protection Trial

A NA study of Coronary Artery Disease and Acute Kidney Injury, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
NA
Development phase
842
Enrollment target
20
Study locations

NCT06027788: Recruiting NA study of Coronary Artery Disease and Acute Kidney Injury, sponsored by Icahn School of Medicine at Mount Sinai.

NCT06027788 is a NA study of Coronary Artery Disease and Acute Kidney Injury that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 842 participants, below the 1,283-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06027788, a NA study of Coronary Artery Disease and Acute Kidney Injury, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
NA
Development phase
842 participants
Enrollment target
20
Study locations

Study Summary

This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.

Primary Outcome

The combined number of patients who experience clinical ischemic strokes and acute kidney injuries that have occurred within 3 days post-randomization.

Interventions

  • DEVICE CardioGard Embolic Protection Cannula
  • DEVICE Standard Aortic Cannula

Study Locations (20)

New York

  • Columbia University Medical Center - New York
  • New York Presbyterian-Cornell Medical Center - New York
  • NYU Langone Hospital Brooklyn - New York
  • Northwell Health - New York
  • Montefiore Medical Center - The Bronx

Indiana

  • Indiana University - Bloomington
  • Indiana Ohio Heart - Fort Wayne

Maryland

  • Johns Hopkins Medicine - Baltimore
  • University of Maryland - College Park

Arkansas

  • CHI St. Vincent Heart Institute - North Little Rock

California

  • Keck Hospital of the University of Southern California - Los Angeles

Georgia

  • Emory University - Atlanta

Louisiana

  • Ochsner Clinic - New Orleans

Maine

  • Maine Medical Center - Portland

Trial Details

FieldValue
Enrollment Target 842 participants
Start Date 2023-09-18
Est. Completion 2027-04-01
Phase NA

What NCT06027788 shows while recruiting

NCT06027788 is an interventional study that assigns participants to a tested intervention. The registered 842 participants enrollment target is mid-sized for trials with a published cap, below the 1,283-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (34% lower).

The record links to 5 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which CardioGard Embolic Protection Cannula is the first listed.

NCT06027788 names 20 study sites across 14 states, led by New York, Indiana, Maryland.

Frequently Asked Questions

What is clinical trial NCT06027788 about?

NCT06027788 is a clinical study titled "CTSN Embolic Protection Trial". This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.

What is the current status of trial NCT06027788?

This trial is currently recruiting. It is a NA study. The enrollment target is 842 participants. The study started on 2023-09-18. Estimated completion is 2027-04-01.

What conditions does trial NCT06027788 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Acute Kidney Injury, Ischemic Stroke, Delirium, Heart Valve Disease.

What interventions are being tested in trial NCT06027788?

The interventions under investigation include: CardioGard Embolic Protection Cannula (DEVICE), Standard Aortic Cannula (DEVICE).

Who is sponsoring clinical trial NCT06027788?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06027788 being conducted?

This trial has 20 study locations across Arkansas, California, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06027788's enrollment target sits among peer trials

842 54th of 219 higher than 166 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06439979 · 843 participants · NA

    Rural Adult and Youth Sun Protection Study

  • NCT06747949 · 844 participants · Phase 3

    A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

  • NCT04831580 · 840 participants · NA

    A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

  • NCT04976881 · 840 participants · NA

    Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06027788, the US trial registry maintained by the National Library of Medicine. NCT06027788 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.